185 related articles for article (PubMed ID: 207983)
1. Serum high-density-lipoprotein cholesterol in women using oral contraceptives, estrogens and progestins.
Bradley DD; Wingerd J; Petitti DB; Krauss RM; Ramcharan S
N Engl J Med; 1978 Jul; 299(1):17-20. PubMed ID: 207983
[TBL] [Abstract][Full Text] [Related]
2. Effect of estrogen/progestin potency on lipid/lipoprotein cholesterol.
Wahl P; Walden C; Knopp R; Hoover J; Wallace R; Heiss G; Rifkind B
N Engl J Med; 1983 Apr; 308(15):862-7. PubMed ID: 6572785
[TBL] [Abstract][Full Text] [Related]
3. Oral contraceptive and postmenopausal estrogen effects on lipoprotein triglyceride and cholesterol in an adult female population: relationships to estrogen and progestin potency.
Knopp RH; Walden CE; Wahl PW; Hoover JJ; Warnick GR; Albers JJ; Ogilvie JT; Hazzard WR
J Clin Endocrinol Metab; 1981 Dec; 53(6):1123-32. PubMed ID: 7298796
[TBL] [Abstract][Full Text] [Related]
4. A randomized prospective study of the metabolic effects of four low-estrogen oral contraceptives.
Briggs MH
J Reprod Med; 1983 Jan; 28(1 Suppl):92-9. PubMed ID: 6403706
[TBL] [Abstract][Full Text] [Related]
5. The effects of different formulations of oral contraceptive agents on lipid and carbohydrate metabolism.
Godsland IF; Crook D; Simpson R; Proudler T; Felton C; Lees B; Anyaoku V; Devenport M; Wynn V
N Engl J Med; 1990 Nov; 323(20):1375-81. PubMed ID: 2146499
[TBL] [Abstract][Full Text] [Related]
6. Incidence of hyperprolactinemia during oral contraceptive therapy.
Reyniak JV; Wenof M; Aubert JM; Stangel JJ
Obstet Gynecol; 1980 Jan; 55(1):8-11. PubMed ID: 7352067
[TBL] [Abstract][Full Text] [Related]
7. Comparison of metabolic and inflammatory outcomes in women who used oral contraceptives and the levonorgestrel-releasing intrauterine device in a general population.
Morin-Papunen L; Martikainen H; McCarthy MI; Franks S; Sovio U; Hartikainen AL; Ruokonen A; Leinonen M; Laitinen J; Järvelin MR; Pouta A
Am J Obstet Gynecol; 2008 Nov; 199(5):529.e1-529.e10. PubMed ID: 18533124
[TBL] [Abstract][Full Text] [Related]
8. Oral contraceptives and lipoprotein metabolism.
Tikkanen MJ; Nikkilä EA
J Reprod Med; 1986 Sep; 31(9 Suppl):898-905. PubMed ID: 3772909
[TBL] [Abstract][Full Text] [Related]
9. Effects of different progestogens on lipoproteins during postmenopausal replacement therapy.
Hirvonen E; Mälkönen M; Manninen V
N Engl J Med; 1981 Mar; 304(10):560-3. PubMed ID: 7453723
[TBL] [Abstract][Full Text] [Related]
10. Metabolic profile of six oral contraceptives containing norgestimate, gestodene, and desogestrel.
Teichmann A
Int J Fertil Menopausal Stud; 1995; 40 Suppl 2():98-104. PubMed ID: 8574257
[TBL] [Abstract][Full Text] [Related]
11. A prospective, one-year study on the effects of two long acting injectable contraceptives (depot-medroxyprogesterone acetate and norethisterone oenanthate) on serum and lipoprotein lipids.
Enk L; Landgren BM; Lindberg UB; Silfverstolpe G; Crona N
Horm Metab Res; 1992 Feb; 24(2):85-9. PubMed ID: 1533383
[TBL] [Abstract][Full Text] [Related]
12. Phytohemagglutin-induced lymphocyte transformation in oral contraceptive users.
Keller AJ; Irvine WJ; Jordan J; Loudon NB
Obstet Gynecol; 1977 Jan; 49(1):83-91. PubMed ID: 63929
[TBL] [Abstract][Full Text] [Related]
13. Pill formulations and their effect on lipid and carbohydrate metabolism.
Brooks PG
J Reprod Med; 1984 Jul; 29(7 Suppl):539-46. PubMed ID: 6481707
[TBL] [Abstract][Full Text] [Related]
14. Effects of oral contraceptives on lipid metabolism.
Krauss RM
J Reprod Med; 1986 Jun; 31(6 Suppl):549-50. PubMed ID: 3723487
[TBL] [Abstract][Full Text] [Related]
15. Effect of synthetic oestrogens and progestagens in oral contraceptives on bile lipid composition.
Down RH; Whiting MJ; Watts JM; Jones W
Gut; 1983 Mar; 24(3):253-9. PubMed ID: 6826111
[TBL] [Abstract][Full Text] [Related]
16. [Do's and don'ts for a woman who has an abnormal lipid pattern and is taking oral contraceptives].
Boyet F
Contracept Fertil Sex (Paris); 1984 Sep; 12(9):1076-7. PubMed ID: 12266510
[TBL] [Abstract][Full Text] [Related]
17. Oral contraceptive estrogen and plasma lipid levels.
Hedlin A; Kuksis A; Geher K
Obstet Gynecol; 1978 Oct; 52(4):430-5. PubMed ID: 714324
[TBL] [Abstract][Full Text] [Related]
18. Formulation and noncontraceptive uses of the new, low-dose oral contraceptive.
Batzer FR
J Reprod Med; 1984 Jul; 29(7 Suppl):503-12. PubMed ID: 6237195
[TBL] [Abstract][Full Text] [Related]
19. The Royal College of General Practitioners' Oral Contraception Study: some recent observations.
Kay CR
Clin Obstet Gynaecol; 1984 Dec; 11(3):759-86. PubMed ID: 6509858
[TBL] [Abstract][Full Text] [Related]
20. The prevalence of hyperlipidemia in women and its association with use of oral contraceptives, sex hormone replacement therapy and nonlipid coronary artery disease risk factors. Canadian Heart Health Surveys Research Group.
Connelly PW; Stachenko S; MacLean DR; Petrasovits A; Little JA
Can J Cardiol; 1999 Apr; 15(4):419-27. PubMed ID: 10322251
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
